Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib for Metastatic Breast Cancer
Recruiting2 awardsPhase 3
Boston, Massachusetts
This trial will compare the effectiveness and safety of olaparib to standard chemotherapy in treating breast cancer that has spread to other parts of the body and has a mutation in the BRCA1 or BRCA2 gene.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.